Clinical trials: Cat Allergy
Cat Allergy
Cat-PAD Exposure Chamber Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01033344
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- Circassia Limited
Cat Allergy
Exposure Chamber Trial With Cat Immunotherapy
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
- Trial name
- NCT00987909
- Testing
- Specific allergen immunotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ALK-Abelló A/S
Cat Allergy
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00867906
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Circassia Limited
Allergy to Cat Dander
Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial
This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients
- Trial name
- IVN-CAT-001B (NCT00718679)
- Testing
- IVN201
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Cat Allergy
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00729508
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Circassia Limited
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
Cat Allergy
Safety of Cat-PAD in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00685711
- Testing
- Cat-PAD
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Circassia Limited